Myeloproliferative Disorder (MPD) and Myelodisplastic Syndrome (MPS)

H 8701; CD34-selection for ex vivo T-cell depletion of mobilized peripheral blood stem cells for recipients of HLA haploidentical related donor stem cell grafts receiving intensive conditioning: This study uses a monoclonal antibody and high dose chemotherapy and radiotherapy combined with a haploidentical allogeneic stem cell transplantation to treat pediatric patients with hematologic malignancies.

H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H: This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.

H12870: Phase I/II Study of anti-Human CD45 monoclonal Antibodies in Patients with Advanced Leukemia prior to Allogeneic Stem Cell Transplantation:  This study uses monoclonal antibodies and high dose chemotherapy and radiotherapy combined with autologous stem cell transplantation to treat patients with hematologic malignancies.

H17529: A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors – BMT CTN Protocol 0201:  This study compares outcomes for patients receiving allogeneic (unrelated) stem cell transplant following high dose chemotherapy (and in some cases radiation therapy). The two groups being compared are patients whose stem cell product comes from donor bone marrow or patients whose stem cell product comes from donor peripheral blood stem cells.

H19164: T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation: This study  looks at T reg cells in patients receiving a haploidentical stem cell transplant following high dose chemotherapy and radiation therapy

H19386: Reduced -Intensity Preparative Regimen With Fludarabine, Busulfan, And Alemtuzumab Followed By Allogeneic Hematopoeitic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases: This study uses a monoclonal antibody and low dose chemotherapy combined with allogeneic stem cell transplantation to treat patients with hematologic disorders (both malignant and non-malignant) who also have other complications such as kidney, liver, or heart disease

H20971: Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis: The purpose of this study is to assess the safety and toxicity of low-dose IL-2 given to patients after receiving a Stem Cell Transplant and to determine whether this drug is helpful in preventing GVHD.

H21580: A Phase I Study Evaluating the use of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation:   This study is an add on study in which patients who have received a haploidentical stem cell transplant are eligible to receive allodepleted T cells following engraftment.  The T-cells may help the immune system recover so that the body can fight infections.

 

©2002, Cell And Gene Therapy, Baylor College of Medicine
One Baylor Plaza, N1002, Houston, TX 77030, (713)798-1246
URL: http://www.bcm.edu/genetherapy Email:cagt@bcm.edu
(Modified: September 21st, 2007 - jb)